Pneumocystis
11
1
1
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 11 trials
100.0%
+13.5% vs benchmark
45%
5 trials in Phase 3/4
0%
0 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (11)
Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation
Short-term Steroid Therapy in Patients With P. Jirovecii Pneumonia Due to HIV / AIDS
Low Dose Trimethoprim-Sulfamethoxazole for the Treatment of Pneumocystis Jirovecii Pneumonia
Positioning Second-line Therapies for Pneumocystis Jirovecii Pneumonia (PCP Alternatives)
How Long Should we Give Steroids for Patients With Severe PCP
Prevalence and Pathogenesis of Lung Disease in a Large HIV Cohort-coordinating Center
Pneumocystis in Patients Over 75 Year
Prospective Observational Study on the Incidence of Opportunistic Fungal Infections
Optimizing the Diagnosis of Pneumocystis in Immunocompromised Patients
Non Invasive Diagnosis of Pneumocystis Pneumonia
Effect of Steroids During Pneumocystis Infection Among Non HIV Immunocompromised Patients